For research use only
| Cat No. | ABC-TC0512 |
| Product Type | Human Colon Cancer Cell Lines |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Product Code | KM12SM; KM12 SM |
KM12SM colorectal carcinoma cells show tetraploidy, high collagenase, mitochondrial dependence, and model metastatic liver homing research.
KM12SM is a human colorectal carcinoma cell line established from a liver metastasis of a primary colon tumor. The cells exhibit epithelial morphology, adherent growth, and a near-tetraploid karyotype with both chromosomal (CIN) and microsatellite instability (MSI). KM12SM carries a KRAS^G13D mutation and demonstrates strong metastatic potential to the liver in vivo. These cells exhibit enhanced proliferation, invasion, ECM adhesion (collagen, fibronectin, laminin), and epithelial-mesenchymal transition (vimentin↑, E-cadherin↓). They secrete pro-angiogenic factors such as VEGF and IL-8, supporting angiogenesis and tumor-stroma interactions. Additionally, proteins EFNA3, CD137L (TNFSF9), and SOSTDC1 have been identified as key mediators of liver-specific metastasis. KM12SM serves as a robust model for studying metastatic colon cancer, angiogenesis, and resistance to targeted therapies.
| Product Code | KM12SM; KM12 SM |
| Species | Human |
| Cat.No | ABC-TC0512 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Colon Cancer Cell Lines |
KM12SM cells are a premier in vitro model for studying colorectal cancer metastasis, especially hepatic dissemination. They are widely used in preclinical evaluations of anti-metastatic agents, KRAS-targeted therapies, and angiogenesis inhibitors. The line also supports investigations into epithelial-mesenchymal transition (EMT), extracellular matrix remodeling, and immune evasion. KM12SM is especially useful for establishing in vivo metastasis models and for high-throughput drug screening aimed at suppressing metastatic progression.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
